Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 Pharmaceutical 2016
Albany, New York, Jan 20,2017
"Multiple
Myeloma (Kahler Disease) - Pipeline Review, H2 2016"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Multiple Myeloma (Kahler Disease) Pipeline Review, H2
2016, provides an overview of the Multiple Myeloma (Kahler Disease)
(Oncology) pipeline landscape.
Multiple
myeloma is a type of cancer that is caused by malignant plasma cells
that proliferate in the bone marrow and produce abnormally high
amounts of a special protein. The exact cause of multiple myeloma is
not clear. Multiple myeloma mainly affects older adults. Symptoms
include anemia, bleeding, nerve damage, skin lesions, bone tenderness
or pain and kidney failure. Treatment includes chemotherapy,
radiation, immunosuppression, and surgery.
*
Report Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Multiple Myeloma (Kahler Disease) Pipeline Review, H2 2016, provides
comprehensive information on the therapeutics under development for
Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis
by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for
Multiple Myeloma (Kahler Disease) and features dormant and
discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II,
Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are
3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the
Universities portfolio in Phase II, Phase I, Preclinical and
Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.
Multiple
Myeloma (Kahler Disease) (Oncology) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide
is built using data and information sourced from Global Markets
Directs proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations
and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
*
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Multiple Myeloma (Kahler Disease) (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Multiple Myeloma
(Kahler Disease) (Oncology) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Multiple Myeloma
(Kahler Disease) (Oncology) therapeutics and enlists all their major
and minor projects.
-
The pipeline guide evaluates Multiple Myeloma (Kahler Disease)
(Oncology) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
*
Reasons to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Multiple Myeloma (Kahler Disease) (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus
of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Comments
Post a Comment